Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

3 Reasons to Leave CSX on the Tracks

By Josh Enomoto, InvestorPlace Contributor

CSX stock is essentially where the economic rubber meets the road. Based on the present situation, that is ominous for the railroad transportation specialist.

10 Key Stocks to Watch Over the Next Few Months

By Josh Enomoto, InvestorPlace Contributor

Because government economic reports are always lagging, investors are fretting over the coming second-quarter figures. But these 10 stocks to watch provide a close-to-real-time indication of sentiment.

Don’t Book a Position on Delta Air Lines Just Yet

By Josh Enomoto, InvestorPlace Contributor

For DAL stock, the loss of consumer confidence is already bad enough. But gauging their willingness to board airplanes with strangers adds a whole new level of anxiety.

Inovio Pharmaceuticals Is Hurting From Remdesivir but It’s Still Standing

By Josh Enomoto, InvestorPlace Contributor

With White House health advisor Dr. Anthony Fauci’s endorsement of Gilead Sciences’ remdesivir, INO stock now seems irrelevant. But that might not be accurate if you look at the broader context.

Co-Diagnostics Is Becoming More Relevant

By Josh Enomoto, InvestorPlace Contributor

A no-name investment in 2019, CODX stock has emerged as one of the most relevant players as Covid-19 diagnostics take center stage.

Load More